The Global Health Body Issues Alert Over Severe Shortage of Obesity Jabs

Under one in 10 people eligible to benefit from weight-loss injections including Wegovy can access them, caution the World Health Organization as it publishes its first guidance on the therapies.

Given over a billion people worldwide currently obese, it is calling for increased and just access to GLP-1 medication.

Based on forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.

"The new guidance affirms that excess weight is a long-term condition that can be treated with comprehensive and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and supply-chain constraints are major hurdles to universal availability to the jabs that can assist patients in reducing considerable weight, explains the organization.

GLP-1 Therapy Shortage

Even in the current most favorable outlook, the supply of such drugs could only cover approximately 100 million people – under 10% of the global need, as stated by the WHO.

The guideline urges governments and firms to expand availability, via strategies like licensing agreements.

Exclusive production rights on semaglutide – the core component of the drug Wegovy – is due to expire in several countries in 2026.

The Way Obesity Drugs Operate

GLP-1 drugs mimick a biological compound to reduce digestion speed, curb appetite and enhance satiety so individuals eat less.

Individuals commonly see weight reduction in the initial weeks of commencing the once-weekly jabs.

Evidence suggests people may put most of the weight back on a year later of halting the medication, because their typical appetite resume.

Being overweight or obese raises your risk for experiencing health problems, including diabetes, heart disease, stroke, and specific malignancies.

Obesity impacts people in all nations and was linked to millions of fatalities worldwide in 2024, as per the WHO.